Logo image of EVOK

EVOKE PHARMA INC (EVOK) Stock Fundamental Analysis

NASDAQ:EVOK - US30049G3020 - Common Stock

5.53 USD
-0.81 (-12.78%)
Last: 8/22/2025, 6:10:56 PM
5.04 USD
-0.49 (-8.86%)
After Hours: 8/22/2025, 6:10:56 PM
Fundamental Rating

3

EVOK gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. EVOK may be in some trouble as it scores bad on both profitability and health. EVOK is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EVOK has reported negative net income.
EVOK had a negative operating cash flow in the past year.
In the past 5 years EVOK always reported negative net income.
EVOK had a negative operating cash flow in each of the past 5 years.
EVOK Yearly Net Income VS EBIT VS OCF VS FCFEVOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

EVOK has a Return On Assets (-31.01%) which is comparable to the rest of the industry.
EVOK has a Return On Equity (-86.94%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -31.01%
ROE -86.94%
ROIC N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVOK Yearly ROA, ROE, ROICEVOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

With an excellent Gross Margin value of 97.36%, EVOK belongs to the best of the industry, outperforming 97.93% of the companies in the same industry.
EVOK's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for EVOK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
EVOK Yearly Profit, Operating, Gross MarginsEVOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

2

2. Health

2.1 Basic Checks

EVOK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EVOK has been reduced compared to 5 years ago.
Compared to 1 year ago, EVOK has an improved debt to assets ratio.
EVOK Yearly Shares OutstandingEVOK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
EVOK Yearly Total Debt VS Total AssetsEVOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

EVOK has an Altman-Z score of -10.46. This is a bad value and indicates that EVOK is not financially healthy and even has some risk of bankruptcy.
EVOK's Altman-Z score of -10.46 is on the low side compared to the rest of the industry. EVOK is outperformed by 67.88% of its industry peers.
A Debt/Equity ratio of 0.86 indicates that EVOK is somewhat dependend on debt financing.
EVOK has a worse Debt to Equity ratio (0.86) than 71.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -10.46
ROIC/WACCN/A
WACCN/A
EVOK Yearly LT Debt VS Equity VS FCFEVOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

EVOK has a Current Ratio of 1.55. This is a normal value and indicates that EVOK is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of EVOK (1.55) is worse than 67.88% of its industry peers.
EVOK has a Quick Ratio of 1.50. This is a normal value and indicates that EVOK is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of EVOK (1.50) is worse than 60.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.5
EVOK Yearly Current Assets VS Current LiabilitesEVOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.29% over the past year.
EVOK shows a strong growth in Revenue. In the last year, the Revenue has grown by 90.02%.
EVOK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 84.95% yearly.
EPS 1Y (TTM)86.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)90.02%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%77.47%

3.2 Future

The Earnings Per Share is expected to grow by 37.19% on average over the next years. This is a very strong growth
Based on estimates for the next years, EVOK will show a very strong growth in Revenue. The Revenue will grow by 52.59% on average per year.
EPS Next Y77.31%
EPS Next 2Y52.8%
EPS Next 3Y37.19%
EPS Next 5YN/A
Revenue Next Year58.22%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EVOK Yearly Revenue VS EstimatesEVOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
EVOK Yearly EPS VS EstimatesEVOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -100 -200 -300

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

EVOK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 3.64 indicates a rather cheap valuation of EVOK.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EVOK indicates a rather cheap valuation: EVOK is cheaper than 97.41% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of EVOK to the average of the S&P500 Index (35.82), we can say EVOK is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.64
EVOK Price Earnings VS Forward Price EarningsEVOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVOK Per share dataEVOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EVOK's earnings are expected to grow with 37.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.8%
EPS Next 3Y37.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVOK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOKE PHARMA INC

NASDAQ:EVOK (8/22/2025, 6:10:56 PM)

After market: 5.04 -0.49 (-8.86%)

5.53

-0.81 (-12.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07
Earnings (Next)11-05 2025-11-05
Inst Owners16.93%
Inst Owner Change-4.2%
Ins Owners1.18%
Ins Owner Change0.59%
Market Cap8.24M
Analysts82.86
Price Target18.36 (232.01%)
Short Float %3.59%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.78%
Min EPS beat(2)-51.52%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-54.68%
Min EPS beat(4)-142.52%
Max EPS beat(4)1.96%
EPS beat(8)4
Avg EPS beat(8)-21.2%
EPS beat(12)6
Avg EPS beat(12)-15.5%
EPS beat(16)9
Avg EPS beat(16)-12.56%
Revenue beat(2)1
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-8.93%
Max Revenue beat(2)5.18%
Revenue beat(4)1
Avg Revenue beat(4)-10.59%
Min Revenue beat(4)-22.51%
Max Revenue beat(4)5.18%
Revenue beat(8)4
Avg Revenue beat(8)-4.95%
Revenue beat(12)5
Avg Revenue beat(12)-4.35%
Revenue beat(16)7
Avg Revenue beat(16)5.56%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.64
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B 1.41
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-3.01
EYN/A
EPS(NY)1.52
Fwd EY27.48%
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS7.78
BVpS3.92
TBVpS3.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.01%
ROE -86.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.36%
FCFM N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.5
Altman-Z -10.46
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y77.31%
EPS Next 2Y52.8%
EPS Next 3Y37.19%
EPS Next 5YN/A
Revenue 1Y (TTM)90.02%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%77.47%
Revenue Next Year58.22%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A
EBIT growth 1Y26.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.35%
OCF growth 3YN/A
OCF growth 5YN/A